Complex Treatment of a Chronic Anal Fissure

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-70
SponsorState Scientific Centre of Coloproctology, Russian Federation

About this trial

This study is aimed at studying the efficacy and safety of treating chronic anal fissure with botulinum toxin versus lateral subcutaneous sphincterotomy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with chronic anal fissure

Disqualifiers

Inflammatory diseases of the colon

Pectenosis

Previous surgical interventions on the anal canal

IV grade internal and external hemorrhoids

Trial design

Design model

Parallel

Treatments tested in this trial

  • IncobotulinumtoxinA 50 U Intramuscular Powder for Solution

    Drug

    Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation. After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution.

  • Lateral subcutaneous sphincterotomy.

    Procedure/Surgery

    The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.

Treatment groups

340 Participants
are divided into 2 treatment groups
Group A: XeominExperimental treatment 1 intervention
Group B: Xeomin controlActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Anal sphincter insufficiency

Frequency of anal sphincter insufficiency according to the Wexner scale incontinence after the surgical intervention. Self reported daily meausure outcome, wich evaluate from 0 - to 20 points (where 0 points = full feacal continence; 20 points = full feacal incontinence).

Time frame
Up to 60 days

Secondary outcomes

1

2-item pain intensity (P2)

Self reported pain intensity after the defecation and during the day after the surgical intervention. Each item is scored 0-10 (0 = no pain; 10 = pain as bad, as can can be).

Time frame
On day 7, 30 and 60
2

Non-Healing Wound

Frequency of post-operative wound epithelialization

Time frame
On day 60
3

Profilometry /sphincterometry findings

Internal sphincter spasm or local internal sphincter spasm by the data of anorectal profilometry / or anorectal sphincterometry

Time frame
On day 30 and 60
4

Temporary disability

Duration of temporary disability

Time frame
Up to 60 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

State Scientific Centre of Coloproctology, Russian Federation

Lead sponsor

St. Petersburg State Pavlov Medical University

Collaborator

Astrakhan State Medical University

Collaborator

Siberian State Medical University

Collaborator

City Clinical Hospital №24, Department of Health City of Moscow

Collaborator

GBUZ MO "Lvovskaia Raionaia Bolnica"

Collaborator

Medical Center ON-CLINIC

Collaborator